mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm

Temsirolimus induces surfactant lipid accumulation and lung inflammation in mice

(2014) Satoshi Washino et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Rapamycin: One Drug, Many Effects

(2014) Jing Li et al.   Cell Metabolism

Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms

(2014) Ignacio Duran et al.   Expert Opinion On Drug Safety

Caution for interstitial lung disease as a cause of CA 15-3 rise in advanced breast cancer patients treated with everolimus

(2014) Annelieke E.C.A.B. Willemsen et al.   INTERNATIONAL JOURNAL OF CANCER

Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma

(2014) Masahiro Nozawa et al.   International Journal of Clinical Oncology

Diagnostic challenges of respiratory adverse events during everolimus treatment

(2014) Annelieke E. C. A. B. Willemsen et al.   Targeted Oncology

Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes

(2013) Bradley J. Atkinson et al.   BJU INTERNATIONAL

Everolimus: side effect profile and management of toxicities in breast cancer

(2013) Elisavet Paplomata et al.   BREAST CANCER RESEARCH AND TREATMENT

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial

(2013) N Colombo et al.   BRITISH JOURNAL OF CANCER

Successful Everolimus Treatment in a Patient with Advanced Pancreatic Neuroendocrine Tumor Who Developed Everolimus-Induced Interstitial Lung Disease on Two Occasions: A Case Report

(2013) Yusuke Nakayama et al.   CHEMOTHERAPY

Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer

(2013) Xiaobei Zhang et al.   CURRENT CANCER DRUG TARGETS

Temsirolimus in the treatment of mantle cell lymphoma

(2013) Krimo Bouabdallah et al.   CURRENT OPINION IN ONCOLOGY

Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia

(2013) Valérie Bernard et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

A Case of Pneumocystis Pneumonia Associated with Everolimus Therapy for Renal Cell Carcinoma

(2013) Yoshinobu Saito et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Adverse Event Profile and Dose Modification of Everolimus for Advanced Renal Cell Carcinoma in Real-world Japanese Clinical Practice

(2013) M. Nozawa et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

(2013) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

(2013) John J Bissler et al.   LANCET

Practical Management of Everolimus-Related Toxicities in Patients with Advanced Solid Tumors

(2013) Viktor Grünwald et al.   ONKOLOGIE

Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis

(2013) Benjamin A. Gartrell et al.   Targeted Oncology

The Effect of mTOR-Inhibition on NF-κB Activity in Kidney Ischemia-Reperfusion Injury in Mice

(2013) A. Kezic et al.   TRANSPLANTATION PROCEEDINGS

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2

(2013) Shinzaburo Noguchi et al.   Breast Cancer

Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials

(2012) Roberto Iacovelli et al.   ACTA ONCOLOGICA

Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA

(2012) J. Yun et al.   ALLERGY

Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma

(2012) L. Albiges et al.   ANNALS OF ONCOLOGY

Everolimus-induced Pneumonitis after Drug-eluting Stent Implantation: A Case Report

(2012) Susumu Sakamoto et al.   CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY

Radiation and Chest CT Scan Examinations

(2012) Asha Sarma et al.   CHEST

Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome

(2012) Donnette A. Dabydeen et al.   EUROPEAN JOURNAL OF CANCER

Drug-induced interstitial lung disease in molecular targeted therapies: high-resolution CT findings

(2012) Fumikazu Sakai et al.   International Journal of Clinical Oncology

Current status of DILD in molecular targeted therapies

(2012) Yoshinobu Saito et al.   International Journal of Clinical Oncology

Patterns of Interstitial Lung Disease During Everolimus Treatment in Patients with Metastatic Renal Cell Carcinoma

(2012) R. Mizuno et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Peripheral blood biomarkers in idiopathic pulmonary fibrosis

(2012) Rekha Vij et al.   Translational Research

Safety of Everolimus by Treatment Duration in Patients With Advanced Renal Cell Cancer in an Expanded Access Program

(2012) Alfonsus J.M. van den Eertwegh et al.   UROLOGY

Total recall of radiotherapy with mTOR inhibitors: a novel and potentially frequent side-effect?

(2011) C. Bourgier et al.   ANNALS OF ONCOLOGY

Role of Chitin and Chitinase/Chitinase-Like Proteins in Inflammation, Tissue Remodeling, and Injury

(2011) Chun Geun Lee et al.   Annual Review of Physiology

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma

(2011) Camillo Porta et al.   EUROPEAN JOURNAL OF CANCER

Current and future directions in mammalian target of rapamycin inhibitors development

(2011) Angelica Fasolo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Two Cases of Everolimus-associated Interstitial Pneumonia in Patients with Renal Cell Carcinoma

(2011) Kentarou Akata et al.   INTERNAL MEDICINE

Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus

(2011) Jose Pablo Maroto et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Serum Clara Cell 16-kDa (CC16) Levels as a Potential Indicator of Active Pulmonary Fibrosis in Systemic Sclerosis

(2011) MINORU HASEGAWA et al.   JOURNAL OF RHEUMATOLOGY

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

(2011) Marianne E Pavel et al.   LANCET

Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors

(2011) E. Vilar et al.   MOLECULAR CANCER THERAPEUTICS

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives

(2011) Marc Dufour et al.   Cancers

Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma

(2010) Dorothy A. White et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Targeting mTOR in renal cell carcinoma

(2010) Gary R. Hudes   CANCER

Phase 3 trial of everolimus for metastatic renal cell carcinoma

(2010) Robert J. Motzer et al.   CANCER

Sirolimus for calcineurin inhibitors in organ transplantation: contra

(2010) Paolo Cravedi et al.   KIDNEY INTERNATIONAL

The Multifunctional Role of mTOR in Innate Immunity: Implications for Transplant Immunity

(2009) M. D. Säemann et al.   AMERICAN JOURNAL OF TRANSPLANTATION

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

(2009) Robert J. Amato et al.   CANCER

7114 Interstitial pneumonitis during RAD-001 treatment: incidence by blinded radiological analysis

(2009) L. Albiges et al.   EJC SUPPLEMENTS

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

(2009) Susan L. Ellard et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

(2009) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of Pneumonitis in Patients with Advanced Non-small Cell Lung Cancer Treated with Everolimus (RAD001)

(2009) Dorothy A. White et al.   Journal of Thoracic Oncology

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

(2008) J. Bellmunt et al.   ANNALS OF ONCOLOGY

Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations

(2008) J LOPICCOLO et al.   DRUG RESISTANCE UPDATES

Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells

(2008) Frank Schmitz et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The TSC-mTOR Signaling Pathway Regulates the Innate Inflammatory Response

(2008) Thomas Weichhart et al.   IMMUNITY